Answers are grounded in this paper and cite their sources.
Retrospective cohort study evaluates short-term survival in young breast cancer patients, highlighting demographic disparities.
e13092 Background: Young-onset breast cancer(diagnosed at age < 40 years) is increasing in incidence,yet contemporary real-world (RW) estimates of age,race,and ethnicity stratified short-term survival remain incompletely characterized outside of population-based registries. Methods: A retrospective cohort study was conducted using the TriNetX Global Collaborative Network,an EHR platform.Female patients with incident BC(ICD-10-CM C50) diagnosed between 1/1/2015–1/1/2025 were included and stratified by age at diagnosis(18–39,40–49,50–64 years).Mortality incidence proportion was defined using all-cause mortality (“Deceased”) and further stratified by race and ethnicity.OS was evaluated over a fixed 3-year horizon to minimize bias from differential follow-up.Comparative analyses were performed using 1:1 propensity score matching (PSM) comparing age groups (18–39 vs 50–64; 40–49 vs 50–64; and 18–39 vs 40–49) with Kaplan–Meier estimation and Cox proportional hazards modeling.Sensitivity analyses included multivariable Cox proportional hazards models adjusting for comorbidities,stage,metastatic status and lines of treatment. Results: Incident cohorts included women 14,219 age18–39, 34,255 age 40–49,and 115,295 age 50–64.Mortality incidence proportion increased with age (18–39: 1.90%, 40–49: 2.16%, 50–64: 3.19%).Across all age groups, mortality incidence proportion was higher among Black vs White patients(18–39:3.40% vs 2.06%;40–49:3.70% vs 2.39%;50–64:5.16% vs 3.53%) and among non-Hispanic vs Hispanic patients (18–39:2.54% vs 1.73%;40–49: 2.45% vs 2.26%; 50–64: 3.74% vs 2.81%).In 3-year PSM analyses using ages 50–64 as the reference,all-cause mortality was lower for 18–39(HR 0.76, 95% CI 0.63–0.90;matched N = 12,327/cohort) and 40–49 (HR 0.88, 95% CI 0.78–0.98;matched N = 29,020/cohort),with no significant difference between 18–39 vs 40–49(HR 0.87, 95% CI0.72–1.04).Findings were consistent in adjusted Cox models (18–39 vs 50–64:aHR 0.78,95% CI0.68–0.89;40–49 vs 50–64:aHR 0.85, 95% CI0.78–0.93;18–39 vs 40–49:aHR 0.92, 95% CI0.79–1.07). Conclusions: In this large EHR-based cohort of incident BC,all-cause mortality increased with age and consistently differed by race and ethnicity,with higher mortality observed among Black and non-Hispanic patients across age strata.After PSM and multivariable adjustment, women diagnosed before age 50 experienced significantly lower short-term mortality risk compared with those aged 50–64.These RW findings provide updated context for age- and demographic-stratified outcomes and support targeted efforts to mitigate disparities through tailored surveillance and treatment strategies in younger BC populations. 3-year propensity score matched (PSM) overall survival. Comparison Matched N (per cohort) HR (95% CI) 18–40 vs 50–64 12,327 0.75 (0.63–0.90) 41–49 vs 50–64 29,020 0.87 (0.78–0.98) 18–40 vs 41–49 12,317 0.86 (0.71–1.04)
No takes yet. Share an insight, caveat, or question.
Afridi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: